Next Article in Journal
The Threshold for Detecting a Rise in Airflow Resistance during Tidal Breathing Is Lower in Older Patients with COPD Than in Healthy People of Similar Age
Previous Article in Journal
Analysis of Hospital Management of Chronic Respiratory Diseases in Light of the “Maps of Health Needs” Project in Poland
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Incidence of mTOR Marker in Tracheal Adenoid Cystic Carcinoma by Immunohistochemical Staining

by
Mihan Pourabdollah Toutkaboni
1,
Mehrdad Farahani
2,
Abdolreza Sadegh
3,
Arda Kiani
4,
Makan Sadr
5,
Kimia Taghavi
6 and
Atefeh Abedini
6,*
1
Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Department of Interventional Pulmonology, Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3
Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4
Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5
Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2020, 88(4), 305-312; https://doi.org/10.5603/ARM.a2020.0120
Submission received: 5 February 2020 / Revised: 27 March 2020 / Accepted: 27 March 2020 / Published: 27 July 2020

Abstract

Introduction: There is an association between the activation of mammalian target of rapamycin (mTOR) signaling and aggressive tumor growth in multiple forms of cancer,including adenoid cystic carcinoma (ACC). ACCs are uncommon yet a malignant form of neoplasms that arises within the secretory glands. Therefore, the aim of this study was to investigate the increase of mTOR in the ACC tumors in order to survey the possibility of treating these tumors with mTOR inhibitors. Material and methods: Samples from known cases of the lung and tracheal ACC were retrievedfrom the archives of the pa-thology department of Masih Daneshvari hospital, and immunohistochemical (IHC) staining for mTOR was performed on them. After preparation of the blocks with specific antibodies, tumor cells with cytoplasmic and/or nuclear expression of mTOR were considered as positive cells by applying a specific scoring method introduced in this study. Results: The paraffin blocks of 26 patients were surveyed and the IHC marker of mTOR was positive in the tumors of 10 patients (38.5%). Out of 10 mTOR positive cases, 5 were females and 5 were males. The primary site of the surveyed tumors was the trachea and bronchus in 12 cases (46%), salivary glands in 7 individuals (27%), and lung tissue in 7 cases (27%), and there was no significant correlation between the primary site of the ACC tumors and the existence of the mTOR markers in them (P = 0.67). From all cases, 13 patients (50%) had cribriform and tubular cells without solid components, 9 cases (34.6%) had cribriform and tubular with less than 30% of solid components, and 4 cases (15.4%) had cribriform and tubular cells with more than 30% of solid com-ponents. There was no significant difference between the morphologies and the existence of mTOR markers in them (P = 0.741). Conclusions: As the incidence of mTOR markers is seen in patients with tracheal ACC, evaluation and scoring of mTOR in these persons can be helpful as further studies can distinguish the use of it in the treatment of the disease.
Keywords: immunohistochemistry; adenoid cystic carcinoma; mTOR immunohistochemistry; adenoid cystic carcinoma; mTOR

Share and Cite

MDPI and ACS Style

Pourabdollah Toutkaboni, M.; Farahani, M.; Sadegh, A.; Kiani, A.; Sadr, M.; Taghavi, K.; Abedini, A. The Incidence of mTOR Marker in Tracheal Adenoid Cystic Carcinoma by Immunohistochemical Staining. Adv. Respir. Med. 2020, 88, 305-312. https://doi.org/10.5603/ARM.a2020.0120

AMA Style

Pourabdollah Toutkaboni M, Farahani M, Sadegh A, Kiani A, Sadr M, Taghavi K, Abedini A. The Incidence of mTOR Marker in Tracheal Adenoid Cystic Carcinoma by Immunohistochemical Staining. Advances in Respiratory Medicine. 2020; 88(4):305-312. https://doi.org/10.5603/ARM.a2020.0120

Chicago/Turabian Style

Pourabdollah Toutkaboni, Mihan, Mehrdad Farahani, Abdolreza Sadegh, Arda Kiani, Makan Sadr, Kimia Taghavi, and Atefeh Abedini. 2020. "The Incidence of mTOR Marker in Tracheal Adenoid Cystic Carcinoma by Immunohistochemical Staining" Advances in Respiratory Medicine 88, no. 4: 305-312. https://doi.org/10.5603/ARM.a2020.0120

Article Metrics

Back to TopTop